Clarus Wealth Advisors Invests $257,000 in Alkermes Plc (ALKS) Stock

Clarus Wealth Advisors acquired a new position in shares of Alkermes Plc (NASDAQ:ALKS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,700 shares of the company’s stock, valued at approximately $257,000.

Several other large investors have also recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in shares of Alkermes by 13.7% in the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock valued at $134,726,000 after buying an additional 319,014 shares during the period. AMP Capital Investors Ltd boosted its stake in shares of Alkermes by 11.0% in the third quarter. AMP Capital Investors Ltd now owns 53,745 shares of the company’s stock valued at $2,732,000 after buying an additional 5,306 shares during the period. Highbridge Capital Management LLC bought a new stake in shares of Alkermes in the third quarter valued at approximately $284,000. Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Alkermes by 206.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 261,977 shares of the company’s stock valued at $13,319,000 after buying an additional 176,442 shares during the period. Finally, AXA bought a new stake in shares of Alkermes in the third quarter valued at approximately $8,487,000. Institutional investors own 98.89% of the company’s stock.

Several equities research analysts recently issued reports on the company. Citigroup set a $62.00 price target on Alkermes and gave the company a “hold” rating in a research note on Thursday. Credit Suisse Group set a $66.00 price target on Alkermes and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Monday, February 5th. JPMorgan Chase & Co. set a $78.00 price target on Alkermes and gave the company a “buy” rating in a research note on Friday, October 27th. Finally, BidaskClub upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Alkermes has a consensus rating of “Hold” and a consensus target price of $64.17.

Alkermes Plc (NASDAQ ALKS) opened at $59.29 on Thursday. Alkermes Plc has a 1 year low of $46.42 and a 1 year high of $64.04. The company has a market cap of $9,120.00, a P/E ratio of -57.56 and a beta of 1.94. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 14th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.32. The business had revenue of $275.37 million during the quarter, compared to the consensus estimate of $251.23 million. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The company’s revenue was up 29.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.02 earnings per share. equities research analysts anticipate that Alkermes Plc will post -0.59 EPS for the current year.

In other news, SVP Iain Michael Brown sold 10,652 shares of the company’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $54.81, for a total transaction of $583,836.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James M. Frates sold 20,932 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $50.51, for a total transaction of $1,057,275.32. Following the transaction, the senior vice president now owns 164,971 shares of the company’s stock, valued at $8,332,685.21. The disclosure for this sale can be found here. Insiders have sold 135,485 shares of company stock valued at $8,227,502 over the last quarter. Company insiders own 5.34% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Clarus Wealth Advisors Invests $257,000 in Alkermes Plc (ALKS) Stock” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2018/02/15/clarus-wealth-advisors-invests-257000-in-alkermes-plc-alks-stock.html.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply